FR2561522A1 - INJECTABLE SOLUTION, IN PARTICULAR FOR PROCESSING CETOSE AND PROCESS FOR PREPARING THE SAME - Google Patents
INJECTABLE SOLUTION, IN PARTICULAR FOR PROCESSING CETOSE AND PROCESS FOR PREPARING THE SAME Download PDFInfo
- Publication number
- FR2561522A1 FR2561522A1 FR8504016A FR8504016A FR2561522A1 FR 2561522 A1 FR2561522 A1 FR 2561522A1 FR 8504016 A FR8504016 A FR 8504016A FR 8504016 A FR8504016 A FR 8504016A FR 2561522 A1 FR2561522 A1 FR 2561522A1
- Authority
- FR
- France
- Prior art keywords
- weight
- glucose
- solution
- nicotinic acid
- injectable solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940102223 injectable solution Drugs 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 239000008103 glucose Substances 0.000 claims abstract description 17
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 17
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 17
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000654 additive Substances 0.000 claims abstract description 8
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 208000007976 Ketosis Diseases 0.000 claims description 11
- 230000004140 ketosis Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 206010002660 Anoxia Diseases 0.000 abstract description 2
- 241000976983 Anoxia Species 0.000 abstract description 2
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 230000007953 anoxia Effects 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- SSZWWUDQMAHNAQ-UHFFFAOYSA-N 3-chloropropane-1,2-diol Chemical compound OCC(O)CCl SSZWWUDQMAHNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000358324 Viverricula indica Species 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000013070 direct material Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
L'INVENTION CONCERNE UNE SOLUTION INJECTABLE CONVENANT EN PARTICULIER POUR LE TRAITEMENT DE LA CETOSE ET UN PROCEDE POUR LA PREPARER. LA SOLUTION INJECTABLE COMPREND 1 A 50 EN POIDS DE GLUCOSE, 0,002 A 2 EN POIDS D'ACIDE NICOTINIQUE, 0 A 10 EN POIDS D'ADDITIF(S) ET 38 A 98,998 EN POIDS D'EAU. CETTE SOLUTION INJECTABLE PEUT SERVIR AU TRAITEMENT DE CAS SERIEUX DE CETOSE ET DE SYNDROME DE FOIE GRAISSEUX, EGALEMENT DE PROCESSUS SEPTIQUES, D'ETATS D'ANOXIE PROLONGEE ET D'ALIMENTATION INSUFFISANTE EN HYDRATES DE CARBONE, AINSI QUE POUR L'ALIMENTATION DES NIVEAUX PAR VOIE PARENTERALE.THE INVENTION CONCERNS AN INJECTABLE SOLUTION SUITABLE IN PARTICULAR FOR THE TREATMENT OF CETOSIS AND A PROCESS FOR PREPARING IT. THE SOLUTION FOR INJECTION CONSISTS OF 1 TO 50 BY WEIGHT OF GLUCOSE, 0.002 TO 2 BY WEIGHT OF NICOTINIC ACID, 0 TO 10 BY WEIGHT OF ADDITIVE (S) AND 38 TO 98.998 BY WEIGHT OF WATER. THIS INJECTIONABLE SOLUTION CAN BE USED FOR THE TREATMENT OF SERIOUS CASES OF CETOSIS AND FATTY LIVER SYNDROME, ALSO OF SEPTIC PROCESSES, CONDITIONS OF PROLONGED ANOXIA AND INSUFFICIENT CARBON HYDRATE SUPPLY, AS WELL AS FOR THE SUPPLY OF THE LEVELS BY PARENTERAL PATH.
Description
La présente invention est relative à une solu-The present invention relates to a solution
tion injectable, notamment pour le traitement de la cétose injection, especially for the treatment of ketosis
et à son procédé de préparation. and its method of preparation.
En élevage, la cétose des vaches est de plus en plus fréquente à mesure qu'augmente la production de lait. La cétose peut être caractérisée par une dégénérescence du foie et par l'apparition d'un foie graisseux. La cause de cette maladie réside en ce que.environ pendant les deux mois In breeding, ketosis of cows is becoming more common as milk production increases. Ketosis can be characterized by degeneration of the liver and the appearance of a fatty liver. The cause of this disease is that about two months
précédant le vêlage, les vaches sont nourries avec un four- before calving, cows are fed
rage trop riche en protéines et pauvre en hydrates de carbone, ce qui se traduit par des troubles du métabolisme au moment rabies is too rich in protein and low in carbohydrates, which translates into metabolic disorders at the time
du vélage. La production de lait diminue en raison du déve- velage. Milk production decreases due to the development of
loppement d'une cétose de lactation. Les espèces Holstein- development of lactation ketosis. Holstein species
Frisonnes et leurs descendances croisées sont particulière- Frisians and their crossed offspring are particularly
ment sujettes à ces troubles du métabolisme. subject to these metabolic disorders.
Dans les cas modérés de cétose, il apparaît une hébétude ou une paralysie, tandis que dans les cas sérieux de cétose, les réserves de graisses de la vache sont libérées, des lipides apparaissent dans le sang et se déposent dans le foie, conduisant à une dégénérescence irréversible du foie In moderate cases of ketosis, there is daze or paralysis, whereas in serious cases of ketosis, the fat reserves of the cow are released, lipids appear in the blood and are deposited in the liver, leading to irreversible degeneration of the liver
et habituellement à la mort de l'animal. and usually on the death of the animal.
Des dégâts économiques extrêmement importants sont provoqués par la cétose dans l'élevage du bétail, puisque ce sont justement les vaches qui donnent beaucoup de lait qui périssent. En plus des pertes matérielles directes, il y a également un dommage génétique, car justement les vaches fournissant de grandes quantités de lait, ne sont pas Extremely important economic damage is caused by ketosis in livestock farming, since it is precisely the cows that give a lot of milk that perish. In addition to direct material losses, there is also genetic damage, because precisely cows providing large amounts of milk, are not
capables de transmettre cette propriété. able to convey this property.
On ne dispose actuellement d'aucune composition pharmaceutique pour le traitement efficace des cas sérieux There is currently no pharmaceutical composition available for the effective treatment of serious cases
de cétose.of ketosis.
On a maintenant découvert que ces cas sérieux peuvent être efficacement traités par une solution injectable comprenant 1 à 50 % en poids de glucose, 0,002 à 2 % en poids d'acide nicotinique, 0 à 10 % en poids d'additif(s) et 38 à It has now been discovered that these serious cases can be effectively treated with an injectable solution comprising 1 to 50% by weight of glucose, 0.002 to 2% by weight of nicotinic acid, 0 to 10% by weight of additive (s) and 38 to
98,998 % en poids d'eau.98.998% by weight of water.
La solution injectable conforme à la présente invention peut contenir un ou plusieurs additifs comme des stabilisants, par exemple du formaldehyde sulfonate de sodium, du thioglycérol ou leurs mélanges; des sels inorganiques, The injectable solution according to the present invention may contain one or more additives such as stabilizers, for example sodium formaldehyde sulfonate, thioglycerol or mixtures thereof; inorganic salts,
par exemple des halogénures de métal alcalin ou alcalino- for example alkali or alkaline metal halides
terreux comme le chlorure de sodium, le chlorure de potassium, le chlorure de calcium, le chlorure de magnésium, l'iodure de potassium ou un mélange de plusieurs sels inorganiques, such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, potassium iodide or a mixture of several inorganic salts,
des vitamines, par exemple la vitamine B6, B12 ou leurs mélan- vitamins, for example vitamin B6, B12 or their
ges; des amino-acides ou leurs dérivés, par exemple le chlorhy- ges; amino acids or their derivatives, for example chlorhy-
drate de L-lysine, la DL-méthionine, la L-valine, le chlorhy- L-lysine drate, DL-methionine, L-valine, chlorhydrin
drate de L-cystéine, le glutamate de sodium ou un mélange de L-cysteine drate, sodium glutamate or a mixture of
plusieurs amino-acides et/ou dérivés d'amino-acides. several amino acids and / or amino acid derivatives.
La solution injectable conforme à la présente invention comprend de préférence 20 % en poids de glucose, The injectable solution according to the present invention preferably comprises 20% by weight of glucose,
0,06 % en poids d'acide nicotinique et 79,94 % en poids d'eau. 0.06% by weight of nicotinic acid and 79.94% by weight of water.
La solution injectable conforme à la présente inventionest préparée par dissolution de 1 à 50 % en poids de glucose, 0,002 à 2 % en poids d'acide nicotinique et 0 à The injectable solution according to the present invention is prepared by dissolving 1 to 50% by weight of glucose, 0.002 to 2% by weight of nicotinic acid and 0 to
% en poids d'additif(s) dans 38 à 98,998 % en poids d'eau. % by weight of additive (s) in 38 to 98.998% by weight of water.
L'eau utilisée pour dissoudre les constituants solides est en général de l'eau distillée, mais une solution The water used to dissolve the solid constituents is usually distilled water, but a solution
saline physiologique peut aussi être employée. physiological saline can also be used.
Les constituants solides peuvent être séparé- Solid constituents can be separated
ment dissous dans de petites portions d'eau, puis les solu- dissolved in small portions of water, then the solutions
tions aqueuses sont combinées et la concentration requise Aqueous mixtures are combined and the concentration required
est ajustée par addition d'eau supplémentaire. is adjusted by addition of additional water.
Dans une variante, les composants solides, c'est-à-dire le glucose, l'acide nicotinique et un ou des Alternatively, the solid components, i.e. glucose, nicotinic acid and one or more
additif(s) sont mélangés, le mélange de poudre est éventuel- additive (s) are mixed, the powder mixture may be
lement broyé, puis dissous dans de l'eau ou une solution saline. La solution obtenue est introduite dans des ampoules ou des flacons. Une stérilisation est effectuée soit avant, soit après l'introduction de la solution dans des then ground, then dissolved in water or saline solution. The solution obtained is introduced into ampoules or flasks. Sterilization is performed either before or after the introduction of the solution into
ampoules ou flacons.ampoules or flasks.
Le mélange des poudres ci-dessus peut éventuel- The mixture of the powders above may possibly
lement être introduit dans des ampoules à poudre et il est dissous directement avant administration On a établi de façon surprenante un effet synergique dans le traitement effectué avec du glucose et de l'acide nicotinique. On a étudié cette synergie sur le mouton en tant que modèle, par rapport à la protection vis-à-vis It can be introduced directly into powder ampoules and is dissolved directly prior to administration. A synergistic effect has been surprisingly established in the treatment with glucose and nicotinic acid. This synergy has been studied on the sheep as a model, with respect to the protection vis-à-vis
de lésions hépatiques induites par voie expérimentale. experimentally induced liver injury.
Quatre groupes d'animaux, comprenant chacun 5 agnelles de type mérinos pesant 30 2 kg, sont soumis aux examens. On prélève du sang chez chaque animal, puis on traite les moutons par voie intra-rumen, avec des solutions suivantes qui lèsent le foie: - un mélange d'huile de paraffine et de tétrachlorure de carbone, selon un rapport volumique de 1 à 1; à la dose de 0,24 ml/kg de poids corporel; - du thioacétamide aqueux à 10 %, à la dose de 0,12 mg/kg de poids corporel; - de l'alcool allylique aqueux à 2 %, à la Four groups of animals, each comprising 5 merino type ewes weighing 2 kg, are subjected to the examinations. Blood is collected from each animal, and the sheep are then treated intratropen, with the following solutions which damage the liver: a mixture of paraffin oil and carbon tetrachloride, in a volume ratio of 1 to 1 ; at a dose of 0.24 ml / kg body weight; 10% aqueous thioacetamide, at a dose of 0.12 mg / kg of body weight; - 2% aqueous allyl alcohol, at the
dose de 0,2 ml/kg de poids corporel. dose of 0.2 ml / kg body weight.
Les agents ci-dessus sont donnés directement l'un après l'autre. De cette façon, il se développe diverses The above agents are given directly one after the other. In this way, it develops various
lésions hépatiques, mais la vie des moutons n'est pas en danger. Hepatic lesions, but sheep's life is not in danger.
A partir du jour du traitement (jour zéro), les animaux sont traités pendant 4 jours (du jour 1 au jour 4), deux fois par jour, avec 50 ml de la solution d'essai. Cette From the day of treatment (day zero), the animals are treated for 4 days (from day 1 to day 4), twice a day, with 50 ml of the test solution. This
solution est administrée par perfusion. solution is administered by infusion.
Le Groupe I des animaux est traité avec une solution saline physiologique, le Groupe II avec 20 % de glucose dans une solution saline physiologique, le Groupe III avec 0,06 % d'acide nicotinique dans une solution saline Group I animals is treated with physiological saline, Group II with 20% glucose in physiological saline, Group III with 0.06% nicotinic acid in saline
physiologique et le Groupe IV avec une solution saline phy- physiological and Group IV with a physiological saline solution
siologique contenant 20 % en poids de glucose et 0,06 % en containing 20% by weight of glucose and 0.06% by weight of
poids d'acide nicotinique.weight of nicotinic acid.
On prélève du sang chez chaque animal, chaque jour avant le premier traitement. Bien que le traitement soit fini le jour 4, on prélève du sang chez chaque animal pen- Blood is taken from each animal every day before the first treatment. Although treatment is finished on day 4, blood is drawn from each animal
dant 5 jours de plus (du jour 5 au jour 9). On détermine l'ac- 5 more days (from day 5 to day 9). We determine the
tivité des enzymes, l'aspartate amino-transférase (AST) et la lactate déhydrogénase (LDH). La moyenne est calculée pour chaque groupe à partir des valeurs d'activité des animau: enzymes, aspartate amino transferase (AST) and lactate dehydrogenase (LDH). The average is calculated for each group from the activity values of the animals:
La lésion du foie est indiquée par une aug- The lesion of the liver is indicated by an increase
mentation de l'activité de ces enzymes. Si les activités normales des enzymes (c'est-à-dire les valeurs d'activité existant avant les lésions hépatiques) sont restaurées, ces lésions sont alors stoppées. Les résultats obtenus sont rasse the activity of these enzymes. If the normal activities of the enzymes (ie the activity values existing before the liver lesions) are restored, these lesions are then stopped. The results obtained are rasse
blés dans les Tableaux I et II.wheat in Tables I and II.
N cm N tn úE 19 EO1 891 "Z 6 E6z 0'6ú (uoTfuaAuT,T ap uoTInTos) AI Ln ú9 801 ZLI 6úZ Zú 9LZ 0'9ú enbTuToDTu apTDe) III IL ú1 LLI IEZ 9ECú 8E9Z 0'8ú (soonlb) II L8 LI L81 Lg 'I1S '0LE 80ú 9'1t (UToW91) I 6 L vp ú ZI o xneuruv, p adnoag anoC nu 'lzTI lad 91TATIDo,P CjTun us iSV T ap 9 TATIOV (GLSv) esu;gsuvaqouTuie Gelu4adse.1 ap 91TATDV N cm N tn úE 19 EO1 891 "Z 6 E6z 0'6ú (uoTfuaAuT, T ap uoTInTos) AI Ln ú9 801 ZLI 6úZ Zú 9LZ 0'9ú enbTuToDTu apTDe) III HE ú1 LLI IEZ 9ECú 8E9Z 0'8ú (soonlb) II L8 LI L81 Lg 'I1S' 0LE 80u 9'1t (UToW91) I 6 L vp ú ZI o xneuruv, p adnoag anoC nu 'lzTI lad 91TATIDo, P CjTun us iSV T ap 9 TATIOV (GLSv) esu; gsuvaqouTuie Gelu4adse.1 ap 91TATDV
TABLEAU IITABLE II
Activité de la lactate d8hydrog4nase (LDH) Activité de la LDH en unité d'activité par litre, au jour Groupe d'animaux O 1 2 3 4 7 9 I (témoin) 603 2828 4532 4179 3442 1892 1010 II (glucose) 645 2734 4648 3450 3058 1527 1090 III (acide nicotinique) 629 2796 4461 3365 2968 1453 991 IV (solution de l'invention) 618 2696 2725 2100 1415 867 636 ru Ln -A ru ré On peut voir d'après les données du Tableau I que Activity of lactate dehydrogenase (LDH) Activity of LDH in unit of activity per liter, per day Group of animals O 1 2 3 4 7 9 I (control) 603 2828 4532 4179 3442 1892 1010 II (glucose) 645 2734 4648 3450 3058 1527 1090 III (nicotinic acid) 629 2796 4461 3365 2968 1453 991 IV (solution of the invention) 618 2696 2725 2100 1415 867 636 ru Ln -A ru r It can be seen from the data in Table I that
dans le groupe témoin (Groupe I) l'activité de l'AST aug- in the control group (Group I), the activity of AST increased
mente jusqu'au jour 2, puis diminue graduellement, mais que la valeur initiale n'est pas retrouvée le jour 9o On observe les mêmes modifications de l'activité until the day 2, then gradually decreases, but the initial value is not found on the day 9o We observe the same modifications of the activity
dans les Groupes II et III.in Groups II and III.
Dans les groupes IV recevant la solution conforme à la présente invention, on peut déjà observer une diminution de l'activité le jour 2 et cette diminution est continue In groups IV receiving the solution according to the present invention, it is already possible to observe a decrease in activity on day 2 and this decrease is continuous.
jusqu'au jour 9, ou la valeur initiale d'activité est obtenue. until day 9, or the initial value of activity is obtained.
L'activité de l'enzyme LDH présente des changements analogues. The activity of the LDH enzyme shows similar changes.
Les données des tableaux I et II montrent claire- The data in Tables I and II clearly show
ment que les activités des enzymes testées ne sont pas modi- that the activities of the enzymes tested are not
fiées par l'utilisation séparée du glucose ou de l'acide nico- by the separate use of glucose or nico-
tinique, si bien qu'il n'y a pas de protection hépatique. tinic, so there is no hepatic protection.
Cependant, une association de ces agents fournit une impor- However, an association of these agents provides an important
tante protection du foie.aunt liver protection.
La solution injectable conforme à la présente inven- The injectable solution according to the present invention
tion est administrée dans l'artère des vaches, de préférence par perfusion, à raison de 1 à 3 fois par jour en général, en fonction de la gravité de la maladie. En plus des cas It is administered in the cows artery, preferably by infusion, usually 1-3 times daily, depending on the severity of the disease. In addition to cases
sérieux de cétose et du syndrome du foie graisseux, la solu- of ketosis and fatty liver syndrome, the solution of
tion injectable conforme a la présente invention peut servir Injection according to the present invention can be used
à traiter des processus septiques, des états de reconvales- to treat septic processes, states of reconvales-
cence, d'anoxie prolongée et d'apport insuffisant en hydrates de carbone, ainsi que pour l'alimentation des animaux par prolonged anoxia and insufficient intake of carbohydrates, as well as for the feeding of animals
voie parentérale.parenteral route.
Outre les dispositions qui précèdent, l'invention comprend encore d'autres dispositions, qui ressortiront de In addition to the foregoing, the invention also includes other arrangements which will be apparent from
la description qui va suivre.the following description.
L'invention sera mieux comprise a l'aide du complé- The invention will be better understood with the aid of
ment de description qui va suivre, qui se réfère à des description which will follow, which refers to
exemples de mise en oeuvre du procédé objet de la présente examples of implementation of the method which is the subject of this
invention.invention.
Il doit être bien entendu, toutefois, que ces exemples de mise en oeuvre sont donnés uniquement à titre d'illustration de l'objet de l'invention, dont ils ne constituent en aucune It should be understood, however, that these examples of implementation are given solely by way of illustration of the subject of the invention, of which they do not constitute any
manière une limitation.way a limitation.
Exemple 1Example 1
On prépare une solution comprenant les constitu- A solution comprising the constituents
ants suivants: glucose 100,0000 g chlorure de sodium 13,0000 g chlorure de potassium 5,0000 g chlorure de calcium 4,2000 g chlorure de magnésium 1,2000 g iodure de potassium 0,0010 g chlorhydrate de L-lysine 0,0900 g DL-méthionine;0,0450 g L-valine 0,0270 g chlorhydrate de L-cystéine 0, 0065 g glutamate de sodium 0,0600 g vitamine B6 0,1000 g vitamine B12 0, 0001 g acide nicotinique 0,3000 g formaldéhyde sulfonate de sodium 1,0000 g eau distillée q s p 500,0000 g Les constituants énumérés ci-dessus sont dissous dans l'eau distillée, puis la quantité de solution obtenue est ajustée à 500 g avec de l'eau distillée. La solution est filtrée à travers un filtre ayant une dimension de pore de 0,45 pm puis introduit dans un flacon à perfusion sous following: glucose 100.0000 g sodium chloride 13.0000 g potassium chloride 5.0000 g calcium chloride 4.2000 g magnesium chloride 1.2000 g potassium iodide 0.0010 g L-lysine hydrochloride 0, 0900 g DL-methionine 0.0450 g L-valine 0.0270 g L-cysteine hydrochloride 0.0065 g sodium glutamate 0.0600 g vitamin B6 0.1000 g vitamin B12 0.0001 g nicotinic acid 0.3000 sodium formaldehyde sulfonate 1.0000 g distilled water qs 500.0000 g The constituents listed above are dissolved in distilled water, then the amount of solution obtained is adjusted to 500 g with distilled water. The solution is filtered through a filter having a pore size of 0.45 μm and then introduced into an infusion vial.
azote; le flacon est ensuite fermé hermétiquement et stéri- nitrogen; the bottle is then sealed and sterilized
lisé à 110 C pendant 10 minutes.read at 110 C for 10 minutes.
Exemple 2Example 2
On répète la procédure qui est décrite dans l'exem- The procedure described in the following example is repeated
ple 1, sauf que l'on utilise 5 g de glucose et 10 g d'acide nicotinique. except that 5 g of glucose and 10 g of nicotinic acid are used.
Exemple 3Example 3
On répète la procédure qui est décrite dans l'exem- The procedure described in the following example is repeated
ple 1, sauf que l'on met en oeuvre 250 g de glucose et 0,01 g 1, except that 250 g of glucose and 0.01 g are used.
d'acide nicotinique.of nicotinic acid.
Ainsi que cela ressort de ce qui précède, l'inven- tion ne se limite nullement à ceux de ses modes de mise en oeuvre, de réalisation et d'application qui viennent d'être décrits de façon plus explicite; elle en embrasse au contraire As is apparent from the foregoing, the invention is in no way limited to those of its modes of implementation, of realization and of application which have just been described more explicitly; it embraces on the contrary
toutes les variantes qui peuvent venir à l'esprit du techni- all the variants that may come to the mind of the
cien en la matière, sans s'écarter du cadre, ni de la portée in this respect, without departing from the scope or scope
de la présente invention.of the present invention.
Claims (4)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2561522A1 true FR2561522A1 (en) | 1985-09-27 |
| FR2561522B1 FR2561522B1 (en) | 1988-10-14 |
Family
ID=10952793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8504016A Expired FR2561522B1 (en) | 1984-03-20 | 1985-03-19 | INJECTABLE SOLUTION, PARTICULARLY FOR THE TREATMENT OF KETOSIS AND A PROCESS FOR PREPARING IT |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS60260510A (en) |
| BE (1) | BE901959A (en) |
| DE (1) | DE3505572A1 (en) |
| FR (1) | FR2561522B1 (en) |
| GB (1) | GB2157561B (en) |
| HU (1) | HU191598B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2245491A (en) * | 1990-06-25 | 1992-01-08 | Medvet Science Pty Ltd | Inhibition of metabolic oxalate formation |
| DE9111598U1 (en) * | 1991-09-18 | 1993-01-28 | Helga Kellermann Mineralgetränke, 5063 Overath | Animal feed |
| GB9216460D0 (en) * | 1992-08-03 | 1992-09-16 | Lilly Industries Ltd | Veterinary method |
| JP2990686B2 (en) * | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | Total infusion containing water-soluble vitamin B |
| JP2001114681A (en) * | 1999-10-18 | 2001-04-24 | Ajinomoto Co Inc | Ketosis improver |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1949774A1 (en) * | 1968-10-03 | 1970-05-27 | Cambrian Chemicals Ltd | Medicines for the treatment of depression |
| FR2173262A1 (en) * | 1972-02-25 | 1973-10-05 | Hoffmann La Roche | |
| GB1477732A (en) * | 1974-06-13 | 1977-06-22 | Otsuka Pharma Co Ltd | Nutrient fluids |
| GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD60477A (en) * | ||||
| GB500770A (en) * | 1937-09-30 | 1939-02-15 | Vitamol Inc | Improvements in or relating to vitamin compositions for use in feeding poultry and livestock, and methods of making the same |
| FR1350101A (en) * | 1962-12-13 | 1964-01-24 | Product for animal feed | |
| GB1289096A (en) * | 1968-10-03 | 1972-09-13 |
-
1984
- 1984-03-20 HU HU841091A patent/HU191598B/en not_active IP Right Cessation
-
1985
- 1985-02-18 DE DE19853505572 patent/DE3505572A1/en active Granted
- 1985-03-18 BE BE1/11215A patent/BE901959A/en not_active IP Right Cessation
- 1985-03-19 FR FR8504016A patent/FR2561522B1/en not_active Expired
- 1985-03-20 JP JP60054707A patent/JPS60260510A/en active Pending
- 1985-03-20 GB GB08507176A patent/GB2157561B/en not_active Expired
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1949774A1 (en) * | 1968-10-03 | 1970-05-27 | Cambrian Chemicals Ltd | Medicines for the treatment of depression |
| FR2173262A1 (en) * | 1972-02-25 | 1973-10-05 | Hoffmann La Roche | |
| GB1477732A (en) * | 1974-06-13 | 1977-06-22 | Otsuka Pharma Co Ltd | Nutrient fluids |
| GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
Also Published As
| Publication number | Publication date |
|---|---|
| HUT37035A (en) | 1985-11-28 |
| GB2157561B (en) | 1988-01-20 |
| DE3505572C2 (en) | 1989-04-20 |
| JPS60260510A (en) | 1985-12-23 |
| GB2157561A (en) | 1985-10-30 |
| FR2561522B1 (en) | 1988-10-14 |
| HU191598B (en) | 1987-03-30 |
| GB8507176D0 (en) | 1985-04-24 |
| BE901959A (en) | 1985-09-18 |
| DE3505572A1 (en) | 1985-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5380761A (en) | Transdermal compositions | |
| DE2556100C2 (en) | ||
| Miller et al. | LIVER INJURY, LIVER PROTECTION, AND SULFUR METABOLISM METHIONINE PROTECTS AGAINST CHLOROFORM LIVER INJURY EVEN WHEN GIVEN AFTER ANESTHESIA | |
| JP2873497B2 (en) | Lipid metabolism regulator | |
| EP0220153B1 (en) | A nutritive emulsion having oxygen-transporting properties, and process for its preparation | |
| JP2000506840A (en) | Complex linoleic acid to attenuate allergic response | |
| JP2002502811A (en) | Propofol compositions containing sulfites | |
| US5492713A (en) | Nutriment preparation | |
| WO2013151341A1 (en) | Injectable composition comprising phosphatidylcholine and method for preparing thereof | |
| EP0460080A1 (en) | Orally administerable calcium supplement for cattle. | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| FR2480603A1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING CYTIDINE DIPHOSPHOCHOLINE | |
| EP0144434A1 (en) | Amino acid-containing fat emulsion | |
| JP3182564B2 (en) | Nutrition composition | |
| FR2561522A1 (en) | INJECTABLE SOLUTION, IN PARTICULAR FOR PROCESSING CETOSE AND PROCESS FOR PREPARING THE SAME | |
| CA1257131A (en) | Total parenteral and enteral nutrition composition | |
| JP2005132747A (en) | Aged pet ageing behavior-improving agent | |
| JP3553992B2 (en) | Metabolic regulator | |
| JPH0720422B2 (en) | Feed additives for ruminants containing vitamins | |
| JP3096052B2 (en) | Lipid metabolism regulator | |
| JP3097196B2 (en) | Stabilization of fat emulsion | |
| WO1997024125A2 (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| Lerner et al. | A fat emulsion for intravenous feeding. | |
| FR2485371A1 (en) | NOVEL COMPOSITION FOR THERAPEUTIC USE BASED ON LYSINE AND ARGININE | |
| JP2007262088A (en) | Nutrition transfusion formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |